What’s New: Scientists backed by the Defense Advanced Research Projects Agency (DARPA) have developed—and patented—a sound-triggered drug delivery system that can be remotely activated inside the human body. While pitched as a medical breakthrough, the technology has clear weaponization potential and fits squarely into the dual-use domain of military and civilian biotech. It’s protected in over 150 countries—and explicitly tied to the U.S. military’s research arm.
Why It Matters: DARPA isn’t just funding experimental medicine. It holds rights to a globally patented implant that responds to external soundwaves. Under the Bayh-Dole Act, the government can license, use, or compel use of inventions it funds—even in commercial settings. This raises serious biosecurity questions as wireless, body-embedded systems move from lab to market.
- The tech was described in a DARPA-funded March 2022 paper authored by researchers from Columbia University, MIT, and George Mason University.
- Patent filings confirm Columbia submitted the invention to the U.S. patent system before publishing the study. A U.S. provisional patent was filed on September 29, 2021, followed by an international patent application (PCT/US2022/077135) on September 28, 2022.
- The patent (WO2023/107765) is active as of March 2025.
- Named inventors on the patent are the same as the lead authors on the paper: Samuel Sia, Rachel D. Field, and Margaret A. Jakus.
- The patent states: “This invention was made with government support under D20AC00004 awarded by the Defense Advanced Research Projects Agency (DARPA). The government has certain rights in the invention.”
Hellbound and Down 